A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis.

Authors:
Address: Tropical Medicine Foundation of Amazonas, Manaus, Brazil. lourives@ig.com.br
Journal:

Publication:

abstract

FUNDAMENTALS: American tegumentary Leishmaniasis (ATL) treatment remains a challenge, since most available drugs are injectable and only a small number of comparative, randomized clinical trials have been performed to support their use. Moreover, treatment outcome may depend on the causative species of Leishmania.

OBJECTIVES:

To evaluate and compare the efficacy and tolerability of meglumine antimoniate, pentamidine isethionate, and amphotericin B in the treatment of ATL caused by Leishmania (Viannia) guyanensis.

METHODS:

185 patients were selected according to the eligibility criteria and randomly allocated into three groups - two groups with 74 patients each, and one group with 37 patients, which underwent meglumine, pentamidine and amphotericin B treatment, respectively. Doses, mode of administration and time periods of treatment followed the current recommendations for each drug. Patients were re-examined one, two and six months after completion of treatment.

RESULTS:

No differences were observed among the therapeutic groups in relation to gender, age, number or site of lesions. Intention-to-treat (ITT) analysis showed efficacy of 58.1% for pentamidine and 55.5% for meglumine (p=0.857). The amphotericin B group was analyzed separately, since 28 patients (75.7%) in this group refused to continue participating in the study. Mild or moderate adverse effects were reported by 74 (40%) patients, especially arthralgia (20.3%) in the meglumine group, and pain (35.1%) or induration (10.8%) at the site of injection in the pentamidine group.

CONCLUSION:

Pentamidine and meglumine show similar efficacy in the treatment of ATL caused by L. guyanensis. Given the low efficacy of both drugs, there is an urgent need for new therapeutical approaches.

Related Articles
Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
AIDS. 1999
Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, Medrano FJ, Sanz J, Picó G, Gómez-Rodrigo J, et al. AIDS. 1999 Jun 18; 13(9):1063-9.
Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
Am J Trop Med Hyg. 2001
Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
Romero GA, Guerra MV, Paes MG, Macêdo VO. Am J Trop Med Hyg. 2001 Nov; 65(5):456-65.
[Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis].
Rev Soc Bras Med Trop. 1996
[Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis].
Correia D, Macêdo VO, Carvalho EM, Barral A, Magalhães AV, de Abreu MV, Orge ML, Marsden P. Rev Soc Bras Med Trop. 1996 Sep-Oct; 29(5):447-53.
Review Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.
Acta Trop. 2011
Review Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.
Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, Andrade CA. Acta Trop. 2011 May; 118(2):87-96. Epub 2011 Mar 21.
Review [Management of cutaneous leishmaniasis in adults and children].
Med Trop (Mars). 2005
Review [Management of cutaneous leishmaniasis in adults and children].
Minodier P, Noël G, Blanc P, Uters M, Retornaz K, Garnier JM. Med Trop (Mars). 2005 Nov; 65(5):487-95.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.